- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Starpharma Holdings Limited (ASX: SPL) today announced that it has received notification of the grant in the US of a key patent specifically relating to the use of SPL7013 to protect against sexually transmitted infections (STIs).
The granting of this patent means that any product presentation of SPL7013 (the active ingredient in VivaGel(R) ) is now protected in the US for an additional five years until 2024, with a possible further 12 month extension to 2025. Given the importance of genital herpes and other STIs in the US, this market is clearly a major commercial opportunity for VivaGel(R) products.
This composition of matter patent is the third patent for VivaGel(R) to be granted in the US, and adds to the already extensive patent coverage for the product in 26 countries covering all major markets.
VivaGel(R) is being developed as a condom coating in collaboration with SSL International plc (LSE: SSL) , the world's leading condom company. SSL markets the global brand Durex(R), and holds approximately 40% of the global branded condom market. Following a deal announced in 2008, SSL has exclusive marketing rights for the VivaGel(R) coated condom.
Starpharma is also developing VivaGel(R) as a vaginal microbicide to prevent the transmission of STIs, including HIV and genital herpes.
Starpharma Holdings Limited (ASX: SPL) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA.
The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. In September 2008 Starpharma signed a full licence agreement with SSL International plc (LSE: SSL) to develop a VivaGel(R) coated condom. Starpharma's receipts under the agreement are estimated to exceed A$100m comprising royalties on SSL sales, further milestone payments, and development support.
For more information, please click here
Tel: +61 3 9866 4722
Mob: +61 417 382 391
Tel: +61 2 9237 2800
Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704
+61 3 8532 2702
Copyright © PrNewswireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Explaining how 2-D materials break at the atomic level January 20th, 2017
Cutting-edge nanotechnologies are breaking into industries November 18th, 2016
STMicroelectronics’ Semiconductor Chips Contribute to Connected Toothbrush from Oral-B That Sees What You Don’t: Microcontroller and Accelerometer help brushers clean their teeth more effectively October 4th, 2016
Particle Works launches range of high quality magnetic nanoparticles August 31st, 2016
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016
Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016
NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016
Programmable materials find strength in molecular repetition May 23rd, 2016
NRL reveals novel uniform coating process of p-ALD April 21st, 2016
New ORNL method could unleash solar power potential March 16th, 2016